Neu­ro­crine’s de­pres­sion drug pass­es Phase 2 tri­al

Neu­ro­crine Bio­sciences re­port­ed that its pill for ma­jor de­pres­sive dis­or­der re­duced scores on a de­pres­sion sever­i­ty scale at about one month in a Phase 2 tri­al.

In the SAV­IT­RI study, 183 adult par­tic­i­pants were as­signed ei­ther Neu­ro­crine’s treat­ment, known as NBI-1065845, or a place­bo tablet.

Pa­tients who re­ceived Neu­ro­crine’s pill saw a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in their scores com­pared to base­line on the Mont­gomery-Ås­berg De­pres­sion Rat­ing Scale at both 28 days and 56 days, meet­ing the pri­ma­ry and key sec­ondary end­points, re­spec­tive­ly, in the mid-stage study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER